Skip to main content

Agile Therapeutics Announces New Agreement with vitaCare® Prescription Services to Improve Access to Twirla®

Agile Plans to Increase Twirla prescriptions filled through telemedicine platforms that utilize vitaCare, such as Twentyeight Health™

Partnership Expected to Augment Future Growth in the Retail Channel, the Company’s Most-Profitable Channel

Expanding Commercial Reach through Strategic Partnerships Continues to Drive Company’s Belief in Achieving 2023 Net Revenue in the Range of $25-$30 Million

PRINCETON, N.J., June 13, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq: AGRX), a women's healthcare company, today announced an agreement with vitaCare Prescription Services, a wholly owned subsidiary of GoodRx, to expand patient access and streamline fulfillment for Twirla (levonorgestrel ethinyl estradiol) transdermal system. VitaCare is a technology and services platform that helps patients navigate key access barriers for branded medications.

“The agreement with vitaCare aligns with our strategy to utilize partnerships to efficiently grow Twirla while continuing to responsibly manage our operating expenses,” said Agile Therapeutics’ Chief Commercial Officer Amy Welsh.

“The goal for the vitaCare partnership is to strengthen Twirla’s already meaningful momentum in our most profitable channel – the retail channel. We believe the partnership with vitaCare will create more opportunity to reach new Twirla patients for whom access has been a barrier, while helping existing Twirla patients stay on therapy. Our on-going plan is to expand our commercial reach, which we expect will contribute to reaching our key 2023 financial goals of generating positive cash flow and delivering net revenue in the range of $25-$30 million.”

Agile continues to grow Twirla’s presence on telemedicine platforms, including Twentyeight Health, in addition to existing partners like Pandia Health and Nurx as more women choose telemedicine for their contraceptive needs. Twentyeight Health is a telehealth company providing affordable access and convenience for reproductive and sexual health and recently acquired the platform assets for SimpleHealth. The Company believes that the Twentyeight Health platform will provide an opportunity for more patients to learn about and access Twirla.

About Agile Therapeutics, Inc.
Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at The Company may occasionally disseminate material, nonpublic information on the Company’s website, Twitter account (@agilether), and LinkedIn account.

About Twirla®
Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Twirla is indicated for use as a method of contraception by women of reproductive potential with a body mass index (BMI) < 30 kg/m2 for whom a combined hormonal contraceptive is appropriate. Healthcare providers (HCPs) are encouraged to consider Twirla’s reduced efficacy in women with a BMI ≥ 25 to <30 kg/m2 before prescribing. Twirla is contraindicated in women with a BMI ≥ 30 kg/m2. Twirla is also contraindicated in women over 35 years old who smoke. Cigarette smoking increases the risk of serious cardiovascular events from CHC use. Twirla is designed to be applied once weekly for three weeks, followed by a week without a patch.

Forward-Looking Statements
Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We may, in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements regarding expected Twirla demand metrics, net revenue and operating expenses for the first quarter of 2023, our projected net revenue and expected operating expenses for 2023, our ongoing and planned manufacturing and commercialization of Twirla®, the potential market acceptance and uptake of Twirla, including the increasing demand for Twirla in 2023, our partnership with vitaCare and its ability to promote growth, our product supply agreement with Nurx, and other telemedicine providers and their ability to drive additional retail channel growth in the second half of 2023, our prospects for future financing arrangements, and our financial condition, growth and strategies. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including risks related to the fact that our estimated Twirla demand metrics, net revenue and operating expenses for the first quarter of 2023 are not final and may be subject to change, our ability to maintain regulatory approval of Twirla and the labeling under any approval we obtain, the ability of Corium to produce commercial supply in quantities and quality sufficient to satisfy market demand for Twirla, our ability to successfully enhance the commercialization of and increase the uptake for Twirla, the size and growth of the markets for Twirla and our ability to serve those markets, regulatory and legislative developments in the United States and foreign countries, our ability to obtain and maintain intellectual property protection for Twirla and our product candidates, the lingering effects of the COVID-19 pandemic on our commercialization efforts, clinical trials, supply chain, operations and the operations of third parties we rely on for services such as manufacturing, marketing support and sales support, as well as on our potential customer base, our ability to regain compliance with the listing requirements of the Nasdaq Capital Market, our strategy, business plans and focus, and the other risks set forth in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.

Matt Riley
Head of Investor Relations & Corporate Communications

Primary Logo

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.